Fig. 4

Summary of ctDNA detection in all patients and all biofluids. a Summary of ctDNA detection in baseline plasma (left of triangle box pair) and urine (right of pair) of DIAMOND ccRCC (left), chRCC (top right), and oncocytoma (oncoC, middle right) patients. Four patients with “other” disease subtypes are also shown (“other,” bottom right). Samples are ranked in descending order according to tumor size (cm). For each data point, the upper left triangle shows the results of INVAR-TAPAS analysis and the bottom right the results of tMAD analysis. Green triangles indicate samples in which ctDNA was detected, white triangles indicate samples in which ctDNA was not detected, gray triangles indicate no data available (because the assay was not applied to that sample, or no sample was available), and pink triangles indicate failed assay. Data points with a black outline indicate patients with metastatic disease at the time of sampling. DIAMOND patients 5842 and 5634 (longitudinal section) are highlighted with an orange box. b Summary of ctDNA detection in baseline (left of triangle box pair) and follow-up (right of pair) plasma of MonReC patients. Each subtype is shown in a separate box (ccRCC, clear cell; pRCC, papillary; chRCC, chromophobe; NA, unknown). The upper left triangle shows the results of QIASeq analysis, the bottom right the results of ichorCNA analysis. Triangle color, as above. Forty-one patients had metastatic disease and, where data was available, the number of metastatic sites is indicated. ctDNA detection are plotted alongside patient characteristics in Additional file 1: Fig. S15